Since its creation, MATWIN relies on a large network of public and private partners all committed to develop oncology innovation.
Large pharmaceutical and diagnostic companies are involved in this original programme since its creation. Their ambitious challenge is to ensure a public-private partnership within oncology innovation and to highlight French research excellence in this area.
Thirteen international major groups (Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Genomic Health, GlaxoSmithKline, Janssen, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) are now part of the MATWIN adventure and are actively involved in the programme. Thanks to their support, MATWIN offers them access to a national showcase of oncology R&D in France.
A partners Club gathering french representatives of MATWIN’s industrial partners meets once a year to :
Help identifying industrial experts for projects’ assessments
Ensure the connection with the MATWIN International Board member’s representative
Evaluate MATWIN’s process as a whole
|Group||Partner Club Representative||Function|
|AMGEN||Leila Kockler||Executive Medical Director|
|ASTRAZENECA||Irène De La Porte||Oncology Medical director|
|BOEHRINGER||Nadine Karam||Oncology Medical Affairs director|
|BMS||Arnaud Bedin||Medical director Oncology-Hématology|
|CELGENE||Jérôme Garnier||Medical director|
|GENOMIC HEALTH||Younes Mahi||Medical Director|
|GSK||Naima Kerbouche||Medical Project Leader, Early phases oncology & academic alliances|
|JANSSEN||Alain Miara||Strategic Alliances director|
|NANOSTRING TECHNOLOGIES||Vincent Puthod||Country Manager|
|NOVARTIS||Lamia Boudiaf||Oncology Medical director|
|PFIZER||Marie-Pierre Chevalier||Strategic Alliances Director|
|PIERRE FABRE||Abderrahim Mahfoudi||Head External Innovation Oncology|
|ROCHE||Patrice Denefle||Head Institut Roche for Research & Translational Medicine|
|SANOFI||Sadek Krouri||Oncology Strategic Alliances director|
WHAT THEY SAY FROM MATWIN
This partnership is in direct line with the group’s development strategy, of which one-third of the products that will pass from preclinical to clinical development in 2018 are in oncology. With its unique expertise, both industrial and academic, MATWIN allows us to identify innovative projects upstream. By taking this position, we aim to accelerate the prospects for treatments and diagnoses for patients.
Oncology and hematological malignancies are one of our five therapeutic priorities. It’s also MATWIN’s fight. It was therefore fitting that we should be involved side by side, at the highest level, through the presence of Robert Radinsky, our Global Vice President for Global Cancer Research. This partnership allows us to have access to early preclinical projects from all over France. Ideally to conclude partnerships but also to increase the influence of France within the group Johnson & Johnson …
Joining the ranks of MATWIN’s industrial partners allows us to access innovative projects from the academic world and to follow the development of ideas of interest which, well-supported, will ultimately lead to the development of innovations. essential for the pharmaceutical industry. By supporting oncology research through initiatives such as this partnership, we give projects the maximum opportunity to mature and reach patients.
Pierre Fabre makes Open Innovation a priority. In 2015, we launched the Pierre Fabre Fund for Innovation, which aims to support biotechs, start-ups or public or private research laboratories in their innovation process. It is therefore natural that our group seeks to intensify its interactions with the MATWIN program, whose objective is also to accelerate the availability of new oncology therapeutics by facilitating cooperation and the reconciliation of expertise.
CANCEROPOLES AND OTHER INSTITUTIONAL PARTNERS
Canceropoles are part of the French cancer research landscape, enabling at regional and inter-regional levels a better coordination of skills and resources, while breaking down barriers between sectors and disciplines. They give rise to large-scale multidisciplinary research networks gathering scientific, clinical, industrial communities, as well as dedicated stakeholders.
Canceropoles partners as well as research institutions such as Gustave Roussy, Curie Institute and all dedicated technology transfer offices (Inserm Transfert, FIST, SATTs, etc.) actively participate to the programme. They help to identify projects with high transfer potential at a national level and then follow and support applicants through the whole MATWIN process. Therefore they get all experts feedbacks on the projects which optimizes transfer processes.
UNICANCER, unique hospital group entirely dedicated to cancer care, is highly involved in the programme, being also MATWIN’s main shareholder. Through the 20 French Comprehensive Cancer Centers, UNICANCER offers a privileged access to a wide top level network of clinical and preclinical KOLs.